Lyon - Centre Léon Bérard
Welcome,         Profile    Billing    Logout  
 2 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pérol, Maurice
ADOPT-lung, NCT06284317: A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

Recruiting
3
290
Europe, RoW
Adjuvant durvalumab
ETOP IBCSG Partners Foundation, AstraZeneca
Non Small Cell Lung Cancer
10/29
03/30
ENCO-BRAF, NCT04526782 / 2019-004621-24: ENCOrafenib With Binimetinib in bRAF NSCLC

Hourglass Jul 2022 - Dec 2022 : Pivotal data readout from ENCO-BRAF trial in combination with Mektovi for NSCLC
Active, not recruiting
2
119
Europe
Encorafenib 75 MG, Binimetinib 15 MG
Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre
Non Small Cell Lung Cancer, BRAF V600E
06/25
03/26
RAISE, NCT05718323: Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

Recruiting
2
44
Europe
Niraparib
ETOP IBCSG Partners Foundation, GlaxoSmithKline, Development Limited
SCLC,Extensive Stage, SLFN11-positive
12/25
06/26
PDC-LUNG-101, NCT03970746 / 2018-002382-19: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Active, not recruiting
1/2
73
Europe
PDC*lung01, Keytruda Injectable Product, Pembrolizumab, Alimta Injectable Product, Pemetrexed
PDC*line Pharma SAS
Non Small Cell Lung Cancer
07/24
12/25
ERICA, NCT04676009: Feasibility of an Acute Physical Exercise Before Treatment Infusion for Metastatic Lung Cancer Patients

Completed
N/A
26
Europe
Exercise arm :
Centre Leon Berard, Claude Bernard University, Lyon Cancer Research Centre, Hospices Civils de Lyon, Inter-university Laboratory of Human Movement Biology
Carcinoma, Non-Small-Cell Lung
12/23
01/24
GHIRINGHELI, François
TARLANEC, NCT06937905: Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Not yet recruiting
3
129
Europe
Standard of Care Chemotherapy, Tarlatamab
Intergroupe Francophone de Cancerologie Thoracique
Neuroendocrine Carcinoma
09/28
03/30
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pérol, Maurice
ADOPT-lung, NCT06284317: A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

Recruiting
3
290
Europe, RoW
Adjuvant durvalumab
ETOP IBCSG Partners Foundation, AstraZeneca
Non Small Cell Lung Cancer
10/29
03/30
ENCO-BRAF, NCT04526782 / 2019-004621-24: ENCOrafenib With Binimetinib in bRAF NSCLC

Hourglass Jul 2022 - Dec 2022 : Pivotal data readout from ENCO-BRAF trial in combination with Mektovi for NSCLC
Active, not recruiting
2
119
Europe
Encorafenib 75 MG, Binimetinib 15 MG
Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre
Non Small Cell Lung Cancer, BRAF V600E
06/25
03/26
RAISE, NCT05718323: Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

Recruiting
2
44
Europe
Niraparib
ETOP IBCSG Partners Foundation, GlaxoSmithKline, Development Limited
SCLC,Extensive Stage, SLFN11-positive
12/25
06/26
PDC-LUNG-101, NCT03970746 / 2018-002382-19: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Active, not recruiting
1/2
73
Europe
PDC*lung01, Keytruda Injectable Product, Pembrolizumab, Alimta Injectable Product, Pemetrexed
PDC*line Pharma SAS
Non Small Cell Lung Cancer
07/24
12/25
ERICA, NCT04676009: Feasibility of an Acute Physical Exercise Before Treatment Infusion for Metastatic Lung Cancer Patients

Completed
N/A
26
Europe
Exercise arm :
Centre Leon Berard, Claude Bernard University, Lyon Cancer Research Centre, Hospices Civils de Lyon, Inter-university Laboratory of Human Movement Biology
Carcinoma, Non-Small-Cell Lung
12/23
01/24
GHIRINGHELI, François
TARLANEC, NCT06937905: Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Not yet recruiting
3
129
Europe
Standard of Care Chemotherapy, Tarlatamab
Intergroupe Francophone de Cancerologie Thoracique
Neuroendocrine Carcinoma
09/28
03/30

Download Options